within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A03F_Propulsives.A03FA10_Acotiamide;

model Acotiamide
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.427,
    Cl = 7.416666666666667e-06,
    adminDuration = 600,
    adminMass = 100 / 1000000,
    adminCount = 1,
    Vd = 0.033,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.020833333333333332,
    Tlag = 10.200000000000001);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Acotiamide</td></tr><tr><td>ATC code:</td><td>A03FA10</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>100</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>33.0</td><td>L</td></tr>
    <tr><td>clearance:</td><td>26.7</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Acotiamide is a gastroprokinetic agent used primarily for the treatment of functional dyspepsia. It works as an acetylcholinesterase inhibitor, enhancing gastric motility and improving gastric symptoms. Acotiamide is approved for use in Japan for functional dyspepsia but is not widely approved in other countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult Japanese volunteers (both sexes) after single oral administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.A.A03FA10 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Acotiamide;
